Low Testosterone Signs at 60: Is TRT Worth It in Your 60s?

The landmark TESTOSTERONE trials (Snyder et al., NEJM 2016) enrolled men over 65 with confirmed hypogonadism and were the first large RCTs to rigorously evaluate TRT benefits in older men. Key findings: TRT significantly improved sexual function, physical activity, bone mineral density, and anemia — but did not improve walking speed or cognitive function at 12 months. This evidence base clarifies what TRT can and cannot achieve for men over 60.

What Low Testosterone Actually Looks Like at 60

By 60, testosterone symptoms rarely show up in isolation the way they might in a younger man — they tend to arrive as a cluster overlapping with other age-related changes, which is exactly why so many cases go unrecognized as hormonal rather than simply attributed to 'getting older.' The most clinically significant signs at this age are erectile dysfunction (reaching 50-70% prevalence by 60), noticeable muscle loss and weakening grip strength that correlates with fall risk, reduced bone density with rising fracture risk, and a general decline in vitality and daily functional capacity. What makes 60 a genuinely useful decade to evaluate testosterone specifically is that this is also when the TESTOSTERONE trials — the most rigorous large-scale research on TRT in older men — actually enrolled their study population, meaning the evidence base for treatment decisions at this age is unusually solid compared to some other age brackets where guidance relies more on extrapolation.

Testosterone Physiology at 60

• •Average total T at 60: approximately 350–480 ng/dL — roughly 30–40% below peak
• •Free testosterone: disproportionately low due to SHBG accumulation over decades
• •LH: often elevated in primary hypogonadism; low/normal in secondary — guides workup
• •Nocturnal testosterone peaks blunted: age-related sleep changes reduce night-time T release
• •Comorbidity burden highest: diabetes, hypertension, cardiovascular disease, medications — all suppress T further

Symptoms Most Clinically Significant at 60

• •Sexual function: ED prevalence reaches 50-70% at 60; absent morning erections common
• •Sarcopenia: muscle loss accelerates markedly; grip strength reduction correlates with fall risk
• •Bone density: vertebral fracture risk rising; T below 200 ng/dL associated with osteoporotic fractures
• •Anemia: testosterone-driven erythropoietin deficiency causes mild normocytic anemia in some hypogonadal men
• •Vitality and energy: functional impairment in daily activities measurable by validated scales
• •Cognitive changes: verbal memory and executive function decline, though TRT effects at 12 months are modest

TRT Risks to Consider at 60

• •Polycythemia: hematocrit above 54% requires dose reduction — more common in older men
• •Prostate: TRT does not cause prostate cancer but raises PSA — baseline PSA required before starting; DRE annually
• •Sleep apnea: TRT may worsen untreated OSA — screen before starting
• •Fertility: complete infertility expected on TRT — irrelevant concern at 60 for most
• •Cardiovascular: TRAVERSE 2023 data show no MACE increase — atrial fibrillation risk mildly elevated

What TRT Realistically Won't Fix at 60

Setting accurate expectations matters as much as understanding the benefits, and the TESTOSTERONE trials are notably useful here precisely because they didn't find improvement in every domain tested — walking speed specifically and cognitive function at the 12-month mark showed no significant benefit over placebo, which is valuable, honest data rather than a disappointing footnote to skip past. This means a 60-year-old starting TRT hoping it will dramatically sharpen his thinking or restore youthful mobility on its own is likely to be disappointed, even though the same treatment reliably helps sexual function, bone density, and anemia in the same population. Realistic goal-setting — targeting the domains with actual trial support (sexual function, bone health, muscle mass, anemia correction) rather than expecting a global reversal of aging — leads to both better treatment decisions and more accurate satisfaction with the results once treatment is underway.

Comorbidities That Complicate the Picture at 60

By 60, most men are managing at least one chronic condition, and several common ones directly interact with both the diagnosis and treatment of low testosterone. Type 2 diabetes and metabolic syndrome both independently suppress testosterone while also being independently common at this age, making it genuinely hard in some men to separate age-related decline from metabolically-driven suppression without a full workup. Cardiovascular disease history matters for weighing TRT's risk-benefit profile, even though the TRAVERSE trial didn't find increased major cardiovascular events overall. Sleep apnea, increasingly common with age and weight gain, both mimics low-T symptoms and can be worsened by TRT itself, making pre-treatment screening particularly relevant at this age. Prostate health considerations also loom larger at this age, since baseline prostate cancer risk rises with age independent of testosterone status, which is exactly why PSA and prostate monitoring are non-negotiable parts of TRT management from 60 onward rather than an optional add-on. This accumulation of interacting conditions is exactly why a 60-year-old's low-T evaluation benefits from a more comprehensive workup than a younger, healthier man might need — not because the core diagnostic approach differs, but because there's simply more to account for when interpreting results and planning treatment.